Calamos Advisors
PCVX icon

Calamos Advisors’s Vaxcyte PCVX Stock Holding History

Calamos Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,794
Closed -$257K – 971
2025
Q1 		$257K Sell
6,794
-3,201
-32% -$256K ﹤0.01% 780
2024
Q4 		$818K Sell
9,995
-16,836
-63% -$1.67M ﹤0.01% 691
2024
Q3 		$3.07M Buy
26,831
+15,298
+133% +$1.38M 0.01% 571
2024
Q2 		$871K Buy
11,533
+1,368
+13% +$93.1K ﹤0.01% 664
2024
Q1 		$694K Buy
+10,165
New +$704K ﹤0.01% 682

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Calamos Advisors's PCVX Position: Q2 2025 in Review

Calamos Advisors sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 6,794 shares — an estimated $257K sold.

Calamos Advisors first reported a position in PCVX in Q1 2024 and held it in 5 quarters. The position peaked at $3.07M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Calamos Advisors reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Calamos Advisors sold 6,794 Vaxcyte shares in Q2 2025, an estimated $257K.
  • Calamos Advisors first reported a position in Vaxcyte in Q1 2024 and held it in 5 quarters.
  • Calamos Advisors's Vaxcyte position peaked at $3.07M in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Calamos Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.